ClinicalTrials.gg

Program

RC28-E protein

Also written as “RC28-E”, “RC28-E injection” and “RC-28E”.

Its studies are mostly in Macular Edema · Macular Degeneration · Diabetic Retinopathy, led by RemeGen.

Furthest: phase 3, since Jan 10, 20235 company-led studies, 3 open or runningNext primary completion: Dec 1, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
RemeGen53 open or runningphase 3since Jan 10, 2023Dec 9, 2018Dec 1, 2028phase 3 · NCT07936487

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2018First study: phase 1 study in Neovascular Age-related Macular DegenerationFirst studyNCT03777254 · 12 enrolled · China
  2. Mar 1, 2021Phase 2 study in Diabetic RetinopathyNCT04782128 · 120 enrolled · China
  3. Jan 10, 2023Phase 3 study in Wet Age-related Macular DegenerationNCT05727397 · 432 planned · China
  4. May 19, 2023Phase 3 study in Diabetic Macular EdemaNCT05885503 · 316 planned · China
  5. Nov 8, 2026Phase 3 study in Diabetic Macular Edema (DME)NCT07936487 · 350 planned · China

Ahead

  1. Dec 1, 2028Primary completion: phase 3 study in Diabetic Macular Edema (DME)NCT07936487

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07936487Diabetic Macular Edema (DME) · China3Not yet recruitingDec 1, 2028350
NCT05885503Diabetic Macular Edema · China3RecruitingJun 2026316
NCT05727397Wet Age-related Macular Degeneration · China3RecruitingNov 29, 2025432
NCT04782128Diabetic Retinopathy · China2UNKNOWNMay 2024120
NCT03777254Neovascular Age-related Macular Degeneration · China1CompletedAug 20, 201912

How it is read

Names in the registry

  • “RC28-E”, 3 entries
  • “RC28-E injection”, 1 entry
  • “RC-28E”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.